Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | ESMO 2022 highlights

Jonathan Spicer • 10 Sep 2022
ESMO 2022
General

Jonathan Spicer, MD, PhD, McGill University Health Centre, Montreal, Canada, shares his highlights of the European Society for Medical Oncology (ESMO) 2022 Congress, including new neoadjuvant data. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jonathan Spicer

2:28
Preoperative chemoimmunotherapy: what this means for surgery
Jonathan Spicer • 27 Apr 2023
2:41
Surgical experience after neoadjuvant chemo-immunotherapy
Jonathan Spicer • 27 Apr 2023
2:01
The challenges associated with surgery for NSCLC
Jonathan Spicer • 10 Sep 2022
1:37
Pharmacodynamic correlates and ctDNA dynamics in the NeoCOAST study
Jonathan Spicer • 12 Sep 2022

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals